anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
According to the World Health Organisation, over 1.5 billion people have musculoskeletal conditions worldwide. Musculoskeletal conditions can cause significant pain, leading to extended periods of immobility and subsequent disability. This causes a loss of fitness, increasing the threat of conditions associated with inactivity, such as cancer and cardiovascular disease. Inactivity will also reduce muscle mass, bringing an increased risk of falls and fall-related injuries. Fortunately, exercise can bring about many health benefits in older age, by improving functional ability and well-being. Additionally, specific programmes which focus on balance and strength reduce the risk and rate of falls. Currently, the most popular rehabilitation modality for seniors is physiotherapy. Unfortunately, there is a huge demand for physiotherapy and there is a waiting period. Waiting for physiotherapy services may have detrimental effects on pain, disability, quality of life, and psychological symptoms in persons with musculoskeletal disorders. A more inexpensive and readily available intervention could therefore be desirable to manage musculoskeletal pain in seniors.

The "Free from Pain" exercise programme, found within the "Free From Pain" exercise book, is a fusion of three different generally accepted exercise programmes. The three programmes are the Otago exercises for lower body strength and balance, the motor control exercises for the lower back and the isometric exercises for the neck and shoulder. Developed by Robertson and Campbell for the New Zealand Accident Compensation Corporation (ACC), the Otago exercise programme aimed to improve balance and strength in patients in order to prevent falls. As a secondary effect, the Otago exercise programme also reduces musculoskeletal pain in community-dwelling older adults. Along with the exercises, the "Free From Pain Exercise Book" also contains 13 chapters. These comprise an introductory chapter, 12 motivation/reason to exercise chapters and 12 exercise-related metaphors.

This is a randomised control trial that will be conducted over a 12-week period. The study population will include 60 participants who will be randomised into a test group and a control group. Participants in the test group (Group 1) will be provided with the "Free From Pain Exercise Book" and participants in the control group (Group 2) would be referred to Physiotherapy (usual care). Participants in the test group (Group 1) will be asked to engage in the 3 sets of exercises within the exercise book for the following 12 weeks. They will be advised to engage in the exercises at least five times a week, whilst reading the informative material once a week. Participants will be asked to provide data in the form of completed surveys at the beginning and the end of the study period.

The aim of the study is to investigate whether the "Free From Pain" exercise Book, containing the preformulated 12-week exercise programme, reduces pain, improves quality of life and decreases fear of falling in people over 60 years of age more than usual care (referral to physiotherapy).
Subjects randomized to the LHB position will be instructed to lay supine on the clinical table, with their head hanging over the edge of the bed as far as possible without discomfort. Subjects will be instructed to administer budesonide 1mg/2cc nebules daily for 12 weeks using the MAD syringe, in the head position to which they were randomized.
During entry, human papillomavirus (HPV) traffics from the endosome to the trans Golgi network (TGN) and Golgi and then the nucleus to cause infection. Although dynein is thought to play a role in HPV infection, how this host motor recruits the virus to support infection and which entry step(s) requires dynein are unclear. Here we show that the dynein cargo adaptor BICD2 binds to the HPV L2 capsid protein during entry, recruiting HPV to dynein for transport of the virus along the endosome-TGN/Golgi axis to promote infection. In the absence of BICD2 function, HPV accumulates in the endosome and TGN and infection is inhibited. Cell-based and in vitro binding studies identified a short segment near the C-terminus of L2 that can directly interact with BICD2. Our results reveal the molecular basis by which the dynein motor captures HPV to promote infection and identify this virus as a novel cargo of the BICD2 dynein adaptor.
<P>PROBLEM TO BE SOLVED: To provide a new protein having activity for inhibiting differentiation and maturation of osteoclast or an osteoclastogenesis inhibiting factor, and to provide a method for producing the protein.  <P>SOLUTION: This new protein having the activity for inhibiting the differentiation and/or the maturation of the osteoclast is produced from human fetal pulmonary fibroblast, wherein the protein has a molecular weight of about 60 KD when measured under a reduction condition and about 120 KD when measured under a non-reduction condition. The method for producing the protein includes a process for isolating the protein from a culture solution of the fibroblast and purifying the isolated protein. Further, the protein is produced in a genetic engineering manner. A cDNA for producing the protein in the genetic engineering manner, an antibody having specific affinity for the protein, and a method for measuring the protein in which the antibody is used are provided in the specification, respectively.  <P>COPYRIGHT: (C)2004,JPO
Disclosed is a method for displaying the flux of a biological signal transduction network as a method for representing the flux of a biological signal transduction network model. The biological signal transduction network model includes a first node, a second node, and a link connecting the first node and the second node. In the biological signal transduction network model, a first part of a change amount over time in the activity of the second node is proportional to the activity of the first node by a first proportional constant. The method comprises the steps in which: a computing device obtains a flux (f_12(0)) flowing from the first node to the second node at an initial time (t0); the computing device calculates a flux (f_12(t)) flowing from the first node to the second node at a time (t), and the computing device displays a link icon indicating the link on a screen. When the flux (f_12(t)) is greater than the flux (f_12(0)), the link icon is displayed in a first-type shape. In contrast, when the flux (f_12(t)) is smaller than the same, the link icon is displayed in a second-type shape. Therefore, the present invention can provide a technique by which the effect of a drug administered to cells is propagated over time through the biological signal transduction network to visually present the process.
Patients receive cediranib maleate 30 mg PO QD on days 1-28. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
The invention provides agkistrodon acutus hemocoagulase-C. The agkistrodon acutus hemocoagulase-C is a hemocoagulase obtained by separating from agkistrodon acutus venin, with a molecular weight of 29213.4D and an isoelectric point of 5.7. The hemocoagulase is composed of two chains alpha and beta, and the chains are connected by a disulfide bond, wherein the chain alpha has an amino acid sequence shown in SEQ ID No. 1, and the chain beta has an amino acid sequence shown in SEQ ID No. 2. The agkistrodon acutus hemocoagulase disclosed by the invention is a serine protease. The serine protease disclosed by the invention is obtained by a purification method comprising the following steps: removing undissolved substances and impurity proteins through fractional precipitation pre-treatment of ammonium sulphate, collecting an active elution peak through two times of anion exchange column chromatography, and obtaining the high-purity venin hemocoagulase after dialysis, ultrafiltration and concentration, and desalination; compared with proteins with activity of not less than 40U/mg, the HPLC analytical purity can achieve more than 95%, and the purification yield is 0.4-0.5% by the weight of the venin raw material.
This is a prospective randomized comparative study. The investigators reviewed all registered patients underwent primary total hip arthroplasty (T.H.A.) at our department up to five years ago. Four hundred sixty three patients were recorded at our data base. After reviewing patients' files, the investigators excluded fifty two patients with follow up less than one year and 29 patients with a previous history of complications. Three hundred eighty two patients were initially eligible for the study. The investigators contacted them by telephone calls in order to ask them to be included in this study. The investigators were unable to contact 57 patients, 51 refused to be included, 31 preferred a personal contact with the surgeon, 14 patients were died and 51 patients did not have an internet access. One hundred seventy eight participants were finally eligible to be included in our research. Only 167 participants completed both electronic and routine follow up and these were our final materials. The investigators designed a group on WhatsApp for all participants included in the study. The questionnaires were sent on the group to be filled by the participants in addition to a request for routine x ray follow up. Also, the investigators used the group to send any announcement, schedule of routine visits and some instructions about how to answer the questionnaires. To keep the privacy of participants' information, every one was asked to resend the file and x- ray pictures to the surgeon private account. The investigators collected data received by all participants and reviewed them. If there was any serious complain or major radiological finding the investigators asked the participant for immediate clinical visit. One month later, the investigators started to recall all participants for routine follow up visit (RV) and reevaluate them clinically and radiologically. The investigators asked participants to calculate total time needed for completion of the questionnaires, time needed for x-ray and we added time needed for reviewing these files. The same was done at the RV including time of transportation. The investigators obtained a written consent from all of the participants after discussion about the aim of the research and the confidentiality of their data. All procedures performed in the study were in accordance with the ethical standards of our department and with the 1964 Helsinki declaration and its later amendments.

the investigators evaluated the effectiveness of the electronic visit (EV) by calculation of the number of missing complications or signs detected at the time of RV and require any interference or close observation
Totally 5 municipalities (25 persons with dementia) will be included in the intervention group, and will receive training in the TIME model. This includes two hours of lectures about dementia and neuropsychiatric symptoms (NPS) and three hours of training and roleplay in using the TIME model. The staff of the home care service will receive the TIME manual and access to the TIME website with access to additional educational and information files. From each municipality, three staff members, called TIME administrators, will receive additional three hours of lectures and roleplay in TIME, and will thereafter have the responsibility for performing the intervention.
The invention relates to a medical composition for treating atherosclerosis. The composition is prepared from the following raw medicine materials in parts by weight: 5-10 parts of walnut kernel, 2-10 parts of drynaria rhizome, 5-30 parts of raidx astragali, 5-10 parts of uniflower swisscentaury root and 5-10 parts of rhizoma alismatis. The formula of the medical composition is simplified, and the curative effect for treating atherosclerosis is definite. The invention also relates to a preparation method of the medical composition. The preparation method comprises the following steps of: preparing the walnut kernels and pulverizing; adding ethanol for percolation; collecting percolation liquid and filtering; decompressing and recovering ethanol and concentrating for standby; completely extracting essential oil with the uniflower swisscentaury roots by a steam distillation method for standby; filtering an obtained aqueous solution by an distillation method for standby; uniformly mixing the drynaria rhizome, the raidx astragali and the rhizoma alismatis; adding water to decoct and then filtering; adding filter liquor to the concentrated percolation liquor and the aqueous solution after extracting the essential oil and concentrating to thick paste; and adding the essential oil and auxiliary materials to prepare oral preparations of granules, tablets, capsules, drop pills or soft capsules, and the like in the pharmacy. By adopting the preparation method can ensure that the medical composition can be conveniently used and the quality of the medical composition can be controlled.
A computer system to assist in distribution of prescription drugs is provided. Prescription drug distribution is a highly regulated and controlled supply chain. Consumers often visit a Pharmacy to fill doctor prescriptions. Payment amounts for prescriptions vary based on health plan coverage negotiated prices. Drugs are made by a Manufacturer but may transition through a Distributor or wholesaler on their way to Pharmacies (where consumers may ultimately make a purchase for use). Pharmacies, Distributors, and Manufacturers keep an inventory of drugs to meet supply demands. Regulations and contracts may prevent transition between stages of a distribution chain. This prevention may be artificial in that the drugs, if allowed to proceed, would still be valid and usable by a consumer. When transition is prevented drugs may be placed in a Drug Morgue and then sold from the Drug Morgue to prevent destruction or other form of handling resulting in wasted inventory.
INTRODUCTION: Cardiogenic shock (CS) is a complex life-threatening condition that results from primary cardiac dysfunction, leading to persistent hypotension and systemic hypoperfusion. Among the therapeutic options for CS are various percutaneous mechanical circulatory support (MCS) devices that have emerged as an increasingly effective hemodynamic support option. Percutaneous therapies can act as short-term mechanical circulatory assistance and can be split into intra-aortic balloon pump (IABP) and non-IABP percutaneous mechanical devices.
AREAS COVERED: This review will evaluate the MCS value while considering the mortality rate improvements. We also aim to outline the function of pharmacotherapies and percutaneous hemodynamic MCS devices in managing CS patients to avoid the onset of end-organ dysfunction and improve both early and late outcomes.
EXPERT OPINION: Given the complexity, acuity and high mortality associated with CS, and despite the availability and efficacy of pharmacological management, MCS is required to achieve hemodynamic stability and improve survival. Various percutaneous MCS devices are available with varying indications and clinical outcomes. The rates of early mortality and complications were found to be comparable between the four devices, yet, IABP seemed to show the most optimal clinical profile whilst ECMO demonstrated its more long-term efficacy.
OBJECTIVES: I. Compare the efficacy of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with or without rituximab in older patients with diffuse mixed, diffuse large, or immunoblastic large cell non-Hodgkin's lymphoma of B-cell lineage with respect to the response rate, time to treatment failure, toxicity, and survival. II. Compare the efficacy of maintenance therapy consisting of rituximab vs observation alone after initial therapy with respect to the time to treatment failure, duration of response, toxicity, and survival of this patient population. III. Determine if maintenance therapy with rituximab results in the conversion of any partial response to complete response.

OUTLINE: This is a randomized study. For the first randomization, patients are stratified according to the number of risk factors (0-1 vs 2-4). For the second randomization, in addition to the number of risk factors, patients are stratified according to objective response to initial induction therapy (partial response vs complete response) and induction therapy (CHOP vs CHOP and rituximab). Patients are randomized to one of two treatment arms. Arm I: Patients receive CHOP chemotherapy comprising cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1 and oral prednisone on days 1-5. Treatment repeats every 21 days in the absence of unacceptable toxicity. Arm II: Patients receive treatment as in arm I. Patients also receive rituximab IV on days -7,-3, 41, and 83. Patients who achieve complete response (CR) after 4 courses of CHOP and remain in CR after 6 courses of CHOP are further randomized to one of two arms. Arm I (Maintenance therapy): Patients receive rituximab IV weekly for 4 weeks. Courses repeat every 6 months for 2 years in the absence of unacceptable toxicity. Arm II: Patients are observed. Patients who achieve partial response (PR) after 6 courses OR PR after 4 courses and then CR after 6 courses receive 2 additional courses of CHOP therapy. Patients are then also randomized to receive either maintenance therapy or observation as above. Patients with stable disease or disease progression are removed from the study. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: Approximately 630 patients will be accrued for this study within 4 years.
Patients will be recruited into cohorts of L-DOS47 escalating doses, with a minimum of 3 and a maximum of 6 patients per cohort for the first and last two dosing cohorts, and a minimum of 1 and a maximum of 2 patients for the middle three dosing cohorts. The starting dose of L-DOS47 will be 0.59 µg/kg; further planned dose levels to be assessed are 0.78, 1.5, 3.0, 6.0, 9.0 and 12.0 µg/kg. The standard of care doses of pemetrexed \[500 mg/m2\] and carboplatin \[AUC6\], respectively, to be administered in combination with L-DOS47, will remain constant across cohorts.
PURPOSE: To provide a soln. for disinfection and preservation which has compatibility with many types of contact lenses, maintains a high level of antimicrobial activity and low toxicity to the tissues of the eyes and does not bond or thicken the disinfectant to the lens surfaces. CONSTITUTION: This soln. for disinfection and preservation contains an antimicrobially effective amt. of the biguanide of the formula ((n) is 1 to 500) or its salts in combination with a buffer agent. The concn. of the biguanide is 0.000001 to 0.0003 wt.%. All of low-mol.wt. oligomers of 4 to 7 in average of (n) high-mol.wt. long-chain polymers up to a mol.wt. of 100,000 and individual monomers of 1 in (n) are used for the biguanide described above, for which the aq. salt (e.g.; hydrochloride) of the biguanide of 2 to 12 in average and more particularly 3 to 8 in the value of (n) is more preferable. The buffer agent described above is preferably a boric acid buffer agent when surfactants are not included in the soln. for disinfection and preservation. Ordinary buffer agents are usable when the buffer agent is combined with a metal ion sealing agent and surfactant.
This is a randomized, placebo-controlled, multi-center study. Patients with persistent disability 6-24 months following an ischemic stroke will be enrolled following confirmation of eligibility. Patients will be randomized 2:1 to undergo a stereotactic surgery and receive a single administration of CTX0E03 Drug Product by intracerebral implantation or undergo sham surgery only (placebo). Patients will be followed for 12 months after surgery with follow-up assessments occurring at various time points over the 12 months. All eligible patients will be assigned a standardized Physical Therapy (PT) program. Patients will complete their daily PT exercises at home for 12 weeks after their surgery.
Patients undergo leukapheresis to obtain PBSCs for transplantation. At least 5 days later, patients with an adequate number of collected cells proceed to high-dose chemotherapy. Patients receive carmustine IV over 4 hours on days -7 to -5, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2. Patients receive an autologous PBSC infusion on day 0.
FIELD: medicine, ophthalmology. SUBSTANCE: agent is lactic acid whey hydrolyzed with enriched lactate and used for curative nutrition. This hydrolyzate can be used for treatment of acute and chronic conjunctivitis. Preparation is diluted with water at ratio = 1:7. Preparation is dropped into conjunctive sac or by jet rinse. EFFECT: enhanced effectiveness of agent.
Promoting child mental health in low-resource or low-income country settings faces numerous challenges in global health research. Although efforts have been made to improve mental health interventions and services for young children, evidence-based interventions (EBIs) for children in low-and middle-income countries (LMICs) are limited. Most mental health EBIs in LMICs have not been scaled widely, and do not focus on early childhood. Mechanisms of action and effectiveness are not well understood. Additionally, most EBIs in LMICs rely on community health workers (CHWs) or a task-shifting approach of implementation because of resource barriers and shortage of mental health professionals (MHPs). However, challenges related to task-shifting (e.g., CHW stress and job burnout) have rarely been studied. For task-shifting to be successful, strategies to overcome challenges faced by CHWs and understanding mechanisms to conduct effective task-shifting are paramount. The overall goal of this study is to address these EBI effectiveness and implementation knowledge gaps by providing a preventive EBI (ParentCorps-Professional Development; PD) that utilizes a task-shifting and a scalable implementation model to promote early childhood students' mental health in a LMIC-Uganda. PD is a school-based EBI and preventive mental health service provision model that supports teachers and school personnel to apply EBI strategies to promote young children's mental health. The PD approach represents a task-shifting model of mental healthcare by shifting mental health preventive duties from professionals to teachers to optimize school children's mental health. Therefore, teachers are considered as CHWs. This study examines impacts and cost-effectiveness of the EBI/PD on teachers and students, as well as examines underlying mechanisms (or theories of change) that contribute to intervention effect. In addition, considering most Ugandan teachers (or CHWs) experience occupational stress that threatens PD uptake, effectiveness, and sustainment, this study will also test a teacher stress management package (T-Wellness, adapted from EBIs) as an enhancement to PD. This study will investigate whether PD + T-Wellness (PDT) is more effective for CHWs/teachers than PD alone.